Arcturus Therapeutics (NASDAQ:ARCT) Price Target Lowered to $21.00 at Citigroup

Arcturus Therapeutics (NASDAQ:ARCT) had its price target decreased by Citigroup from $66.00 to $21.00 in a report released on Thursday,Benzinga reports. Citigroup currently has a buy rating on the biotechnology company’s stock.

Other research analysts also recently issued reports about the company. Wall Street Zen downgraded Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. HC Wainwright lowered their target price on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Roth Mkm assumed coverage on Arcturus Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $20.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, January 21st. Finally, Piper Sandler dropped their target price on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $30.33.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $7.25 on Thursday. The firm has a market cap of $206.05 million, a price-to-earnings ratio of -3.05 and a beta of 2.40. Arcturus Therapeutics has a 52-week low of $5.85 and a 52-week high of $24.17. The firm has a 50 day moving average price of $7.30 and a two-hundred day moving average price of $11.32.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.11). The firm had revenue of $7.20 million for the quarter, compared to analyst estimates of $14.32 million. Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%. As a group, equities research analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in Arcturus Therapeutics during the first quarter worth $128,000. Millennium Management LLC bought a new stake in shares of Arcturus Therapeutics during the first quarter worth about $4,892,000. Goldman Sachs Group Inc. raised its holdings in shares of Arcturus Therapeutics by 9.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock worth $5,398,000 after acquiring an additional 42,636 shares during the last quarter. Acadian Asset Management LLC bought a new position in Arcturus Therapeutics in the 1st quarter valued at about $701,000. Finally, Strs Ohio acquired a new position in Arcturus Therapeutics during the 1st quarter valued at about $89,000. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics News Roundup

Here are the key news stories impacting Arcturus Therapeutics this week:

• Positive Sentiment: Company reiterated clinical progress: Arcturus outlined launch of a 12‑week Phase II cystic fibrosis (CF) trial and said it expects regulatory clarity for ARCT‑810 in 2026, which supports longer‑term pipeline value. Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026
• Positive Sentiment: Major sell‑side firms still carry sizable upside even after cuts — Piper Sandler kept an overweight rating and, despite lowering its target, the revised target implies significant upside versus the current price. This signals continued analyst conviction in the stock’s longer‑term recovery. Piper Sandler price target update (Benzinga)
• Neutral Sentiment: Arcturus will present at the Leerink Partners 2026 Global Healthcare Conference (fireside chat on March 11), which gives management a platform to update investors on trials and regulatory timing. Arcturus Therapeutics to Attend Upcoming Investor Conference
• Neutral Sentiment: Short‑interest data in recent reports appear inconsistent/zeroed out (shows 0 shares and NaN increases), so there’s no reliable signal from short interest yet. Investors should treat those figures with caution.
• Negative Sentiment: Q4 results disappointed: EPS and revenue missed analysts’ expectations (revenue roughly $7.2M vs. ~$14.3M consensus) and margins remained negative — this is the primary near‑term catalyst pushing the stock lower. Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
• Negative Sentiment: Market reaction and coverage changes: Several firms cut price targets substantially (examples include Citigroup and Piper Sandler reducing multi‑year targets), which increases near‑term downward pressure despite some retained buy/overweight ratings. Citigroup lowers price target on Arcturus (Tickerreport)

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.